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LINE-1 (L1) retrotransposons are mobile genetic
elements comprising 17% of the human genome.
New L1 insertions can profoundly alter gene function
and cause disease, though their significance in
cancer remains unclear. Here, we applied enhanced
retrotransposon capture sequencing (RC-seq) to
19 hepatocellular carcinoma (HCC) genomes and
elucidated two archetypal L1-mediated mechanisms
enabling tumorigenesis. In the first example, 4/19
(21.1%) donors presented germline retrotransposi-
tion events in the tumor suppressor mutated in
colorectal cancers (MCC). MCC expression was
ablated in each case, enabling oncogenic b-cate-
nin/Wnt signaling. In the second example, suppres-
sion of tumorigenicity 18 (ST18) was activated by
a tumor-specific L1 insertion. Experimental assays
confirmed that the L1 interrupted a negative feed-
back loop by blocking ST18 repression of its
enhancer. ST18 was also frequently amplified in
HCC nodules from Mdr2/ mice, supporting its
assignment as a candidate liver oncogene. These
proof-of-principle results substantiate L1-mediated
retrotransposition as an important etiological factor
in HCC.Cell 153, 101–111, MaINTRODUCTION
Liver cancer accounts for 9%of all cancer deaths worldwide and
12% in developing countries (Jemal et al., 2011). Pathological
inspection indicates hepatocellular carcinoma (HCC) in 80%
of liver tumors, with infection by hepatitis B virus (HBV) and
hepatitis C virus (HCV) being the most prevalent risk factors, fol-
lowed by chronic alcoholism (Jemal et al., 2011; Perz et al., 2006;
Tateishi and Omata, 2012). Although early detection and moni-
toring of patients with liver cirrhosis can substantially improve
5 year survival rates, progression to advanced HCC reduces
average life expectancy to less than 8 months (Llovet et al.,
2008). As for other cancers, genome and exome resequencing
have elucidated molecular pathways frequently perturbed in
HCC (Guichard et al., 2012; Tateishi and Omata, 2012; Totoki
et al., 2011), potentially enabling therapeutic intervention
informed by the mutational signature of a given tumor. The
capacity to catalog the full spectrum of genetic aberrations
occurring in HCC is therefore of critical importance.
LINE-1 (L1) retrotransposons are a major source of endoge-
nous mutagenesis in humans (Burns and Boeke, 2012; Levin
and Moran, 2011). These mobile genetic elements utilize
a ‘‘copy-and-paste’’ mechanism to retrotranspose to new
genomic loci, with such success in germ cells that 500,000 L1
copies comprise 17% of the genome (Lander et al., 2001). Of
these copies, only 80–100 are transposition competent, with
distinct subsets of frequently active—or ‘‘hot’’—L1s driving
insertional mutagenesis in each individual genome (Beck et al.,rch 28, 2013 ª2013 Elsevier Inc. 101Open access under CC BY license.
Table 1. Nonreference Genome Insertions Detected by RC-Seq
Donor Gender Virus Age
Germline
Insertions
Private
Germline
Insertions
Validated
Tumor-Specific
Insertions
12 M HCV 65 2,082 202 3
15 M HBV 53 1,845 216 1
21 M HCV 51 2,019 271 0
29 M HCV 52 1,602 44 0
32 M HBV 73 1,681 100 0
33 F HCV 57 1,982 234 2
35 F HCV 78 1,786 96 0
42 F HCV 67 1,594 43 0
47 M HBV 61 1,581 77 2
48 M HBV 35 1,744 212 0
49 M HCV 68 1,644 58 0
60 M HCV 48 1,570 33 0
62 M HBV 33 1,750 153 0
70 M HCV 55 1,673 82 0
86 F HBV 56 1,701 50 0
89 M HBV 60 1,739 163 4
95 M HBV 54 1,773 88 0
106 M HBV 60 2,141 48 0
116 M HBV 62 1,532 71 0
F, female; M, male. Please see Tables S2 and S3 for supporting data and
details.2010; Brouha et al., 2003). Retrotransposon insertions can
profoundly alter gene structure and expression (Cordaux and
Batzer, 2009; Faulkner et al., 2009; Han et al., 2004; Levin and
Moran, 2011) and have been found in nearly 100 cases of
disease (Faulkner, 2011; Hancks and Kazazian, 2012). L1 activity
is consequently suppressed in most somatic cells by methyla-
tion of a CpG island in the internal L1 promoter (Coufal et al.,
2009; Swergold, 1990). By contrast, L1 is often hypomethylated
in tumor cells, removing a key obstacle to retrotransposition
(Levin and Moran, 2011).
Despite this failure to repress L1 transcription, only a handful
of L1 insertions had been found in human tumors until very
recently (Liu et al., 1997; Miki et al., 1992). High-throughput L1
integration site sequencing has since revealed 9 and 69 de
novo L1 insertions, respectively, in lung and colorectal tumors
(Iskow et al., 2010; Solyom et al., 2012), whereas cancer genome
resequencing elucidated a further 183 tumor-specific L1 inser-
tions in colorectal, ovarian, and prostate cancer (Lee et al.,
2012). In this latter study, more than half of all insertions were
found in a single colorectal tumor; the other individuals pre-
sented fewer than five tumor-specific L1 insertions on average.
These data suggest L1mobilization may be common in epithelial
tumors, though the reasons for possible cell-of-origin restriction
are currently unknown.
Tumor-specific L1 retrotransposition has not previously been
observed in HCC. For several reasons it is, however, a logical
cancer in which to expect L1 mobilization. First, HCC is epithelial
in origin. Second, HBV and HCV infection are common in HCC;
viruses can suppress host defense factors, such as APOBEC
proteins, that control retrotransposon activation. APOBEC3G
has been shown, for instance, to inhibit both HBV replication
and endogenous retrotransposition (Esnault et al., 2005; Turelli
et al., 2004). Third, liver inflammation precedes HCC and may,
via cellular stress, stimulate retrotransposition (Fornace and
Mitchell, 1986). Given these facts, we aimed to map L1 integra-
tion sites in HCC using retrotransposon capture sequencing
(RC-seq) and assess their impact upon oncogenic and tumor
suppressor pathways.
RESULTS
Enhanced Retrotransposon Capture Sequencing
To test the hypothesis that L1 mobilizes in HCC, we applied
an updated RC-seq protocol to 19 HCC tumors and matched
adjacent liver tissue that were confirmed positive for HBV
or HCV infection (Table 1). An earlier RC-seq design (Baillie
et al., 2011) was modified to incorporate multiplex liquid-phase
sequence capture (Figure 1A) using a refined probe pool (Table
S1 available online) and a reduced insert size of 220 nt, which
enabled high-confidence assembly of overlapping paired-end
150 nt reads (Figure 1B). This change simplified genomic align-
ment and, more importantly, enabled single-nucleotide resolu-
tion of retrotransposon integration sites (Figure 1C).
After stringent filtering and mapping, an average of 2 million
reads were retained per library with >95% identity to active L1,
Alu, and SVA families, as well as the most recently active human
LTR endogenous retroviruses (Table S2). Optimized sequence
capture led to a 4-fold increase in reads aligned to nonreference102 Cell 153, 101–111, March 28, 2013 ª2013 Elsevier Inc. Open accesgenome L1s per library compared to previous RC-seq based on
solid-phase arrays and similar sequencing depth (Baillie et al.,
2011). The improved resolution of RC-seq also allowed us to
discriminate a required minimum of two unique amplicons in
support of any nonreference genome insertion (see Extended
Experimental Procedures).
Frequent Retrotransposition in the Human Germline
A total of 7,689 nonreference genome insertions were detected
in 19 tumor (T) samples and 19 matched nontumor (NT) liver
samples. Of these, we annotated 7,644 as putatively germline
(Table S3) because of their presence in (1) databases of retro-
transposon-induced polymorphisms (Beck et al., 2010; Ewing
and Kazazian, 2010; Iskow et al., 2010; Wang et al., 2006), (2)
pre-existing insertions annotated by pooled blood RC-seq (Bail-
lie et al., 2011), (3) multiple individuals, or (4) nontumor liver. L1,
Alu, SVA, and LTR-flanked retrotransposons comprised 13.5%,
81.8%, 4.3%, and 0.4% of germline insertions, respectively. As
expected, L1-Ta and L1-pre-Ta (99.3%) and AluY (99.7%) were
the main L1 and Alu subfamilies active in germ cells (Mills et al.,
2007).
A total of 2,241 germline insertions were found in only one indi-
vidual each (Table 1 and Table S3) andwere not annotated by the
aforementioned retrotransposon polymorphism databases, sug-
gesting that thesewere private or raremutations or, alternatively,
had occurred in early development (Garcia-Perez et al., 2007;
Kano et al., 2009). RC-seq detected 1,489 (66.4%) insertions
at both their 50 and 30 ends, enabling us to model the charac-
teristic sequence features of L1-mediated retrotransposition.s under CC BY license.
Figure 1. Enhanced RC-Seq
(A) Multiplexed Illumina libraries are hybridized to liquid-phase sequence
capture probes targeting the 50 and 30 ends of recently active human retro-
transposons (Table S1).
(B) Paired-end 150-mer sequencing of 220 nt inserts enables ‘‘contig’’
assembly of each read pair into a single read.
(C) Assembled reads with a 50 or 30 section of an active retrotransposon at one
end (highlighted in red) are retained. The opposite end is then aligned to the
reference genome, indicating the position of known and novel insertions.Without any additional sequencing, we were able to analyze
insertions for the presence of target site duplications (TSDs),
an L1-endonuclease recognition motif (Jurka, 1997), and a polyA
tail (Figures 2A and 2B). These features consistently resembled
target-primed reverse transcription (TPRT) for L1, Alu, and
SVA, again illustrating the primary retrotransposition mechanism
in germ cells (Cost et al., 2002; Jurka, 1997).
We also identified 160 previously undetected full-length
(>99.9%) L1 copies, including 115 with paired 50/30 detection
(Figure 2C; Table S4) and 82 each found in a single donor only.
All were annotated as L1-Ta or pre-Ta. These potentially ‘‘hot’’
L1s added to a recent cohort of full-length L1 insertions found
in six geographically diverse individuals via fosmid screening
and sequencing (Beck et al., 2010). Of 68 L1 insertions reported
by Beck et al. (2010), we detected 49 (72.1%), including 15/18
(83.3%) with an allelic frequency >5%. Of the 49 insertions
common to both studies, 46 (93.9%) were base-pair identical
in genomic position. These results confirm strong agreement
between RC-seq and the conservative fosmid-based approach
of Beck et al. (2010).Cell 153, 101–111, MEach individual genome contained on average 244 nonrefer-
ence genome L1 insertions, a figure 60% and 80% higher,
respectively, than recent L1 insertion site sequencing on cell
lines (Ewing and Kazazian, 2010) and single cells (Evrony et al.,
2012). Therefore, to assess the RC-seq false-positive rate, we
randomly selected 200 germline insertions (173 Alu, 14 L1, 11
SVA, and 2 LTR) for site-specific PCR validation (Table S5). Of
these, we confirmed 197 (98.5%). The remaining three insertions
(2 SVA and 1 Alu) occurred in repetitive genomic regions and
were detected by multiple unique reads in at least ten different
samples each, indicating that these may have represented
PCR false negatives. These comparisons and experiments
together demonstrate the sensitive and accurate mapping of
bona fide retrotransposition events by RC-seq and further high-
light ongoing L1 retrotransposition in the global human popula-
tion (Beck et al., 2010; Ewing and Kazazian, 2010; Huang
et al., 2010; Iskow et al., 2010).
Activation of b-Catenin/Wnt Signaling via L1-Mediated
Ablation ofMCC
To assess the potential tumorigenic consequences of the identi-
fied nonreference genome insertions, we selected and validated,
by insertion site PCR, 31 L1, Alu, and SVA insertions in genes
generally implicated to play a causal role in cancer (Futreal
et al., 2004) or specifically in HCC (Guichard et al., 2012),
including L1 insertions in the proto-oncogene ALK and the tumor
suppressor FHIT (Table S5). Quantitative RT-PCR indicated,
however, that 28/31 of these germline insertions did not signifi-
cantly perturb host gene expression in tumor or nontumor liver
versus control liver from five unaffected individuals (data not
shown).
Strikingly, the three remaining insertions all coincided with
strong inhibition of the tumor suppressor mutated in colorectal
cancers (MCC) (Higgins et al., 2007). MCC is expressed in liver
(Senda et al., 1999) and regulates the oncogenic b-catenin/Wnt
signaling pathway frequently activated in HCC (Fukuyama
et al., 2008; Guichard et al., 2012; Totoki et al., 2011). In vitro
experiments have established that siRNA knockdown of MCC
mRNA dramatically increases b-catenin (CTNNB1) expression,
whereas MCC overexpression inhibits cellular proliferation (Fu-
kuyama et al., 2008; Matsumine et al., 1996). MCC is also an
intriguing HCC candidate gene because of its genomic proximity
to APC, a major tumor suppressor mutated in familial adenoma-
tous polyposis preceding colorectal cancer (Groden et al., 1991;
Kinzler et al., 1991). It is important to note that mutated APC
occurs in <2% of HCC cases versus >60% of colorectal carci-
nomas (Guichard et al., 2012; Powell et al., 1992). We therefore
hypothesized that germline retrotransposition events specifically
inhibited MCC tumor suppressor function in liver. To test this
prediction, we assessed the impact of each MCC mutation
upon MCC, APC, and CTNNB1 expression.
Three germline retrotransposon insertions were found in
MCC. The first of these, labeled MCC-L1-a, comprised a
5.3 kb L1-Ta oriented in sense to MCC in donors 70 and 95
(Figure 3A). Another L1-Ta, labeled MCC-L1-b, was full-length
(6 kb), occurred at a different genomic position in donor 116,
and was oriented antisense toMCC (Figure 3B). Finally, in donor
33, we found an AluY (MCC-Alu; Figure 3C) inserted in anarch 28, 2013 ª2013 Elsevier Inc. 103Open access under CC BY license.
Figure 2. Characteristics of Recent Germline Retrotransposition in Humans
(A) Distributions of target site duplication length and poly-A tail length for L1, Alu, and SVA.
(B) Consensus sequence motifs (Crooks et al., 2004) at integration sites closely resembled the canonical L1 endonuclease recognition sequence.
(C) Genomic positions (indicated by red lines) of 115 previously unobserved full-length L1 insertions detected at both termini by RC-seq.
Please see Tables S4 and S5 for further supporting data.ENCODE-delineated enhancer (Thurman et al., 2012). Insertion
site PCR revealed that MCC-L1-a was heterozygous in donor
70 and homozygous (or possibly hemizygous) in donor 95,
whereas MCC-L1-b and MCC-Alu were heterozygous in donor
116 and donor 33, respectively (Figure 3D).
An immunoblot indicated that MCC was dramatically less
abundant in tumor and nontumor samples from all four donors
compared with control liver tissue (Figure 4A). By contrast,
CTNNB1 was expressed much more strongly in the affected
donors than in controls (Figure 4A). This inverse relationship
was consistent with MCC suppression of CTNNB1 through
protein-protein interactions, as reported elsewhere (Fukuyama
et al., 2008). As a corroborating example, immunohistochemistry
performed on tumor and nontumor tissue from donor 116 con-
firmed cytoplasmic CTNNB1 accumulation (Figure S1), a strong
indicator that the factors controlling CTNNB1 expression outside
of the plasma membrane were absent and that many cells had
entered a proliferative state (Nhieu et al., 1999).
Quantitative RT-PCR indicated that MCC transcription was
severely reduced (p < 0.02–p < 0.002, t test, degrees of freedom
[df] = 19) in all four tumors compared to normal liver (Figures 4B).
MCC-L1-a and MCC-L1-b strongly suppressed MCC expres-
sion in donor 95 and donor 116’s nontumor liver, respectively
(Figure 4B). MCC was also significantly downregulated in tumor
versus nontumor in all four individuals (p < 0.0001, t test, df = 4).
Capillary sequencing of each MCC exon revealed only one
missense mutation, a homozygous SNP (570 A > G) in donor
33 MCC exon 5, producing an Arg > Lys substitution in the puta-
tive CTNNB1 binding domain of MCC (Fukuyama et al., 2008).104 Cell 153, 101–111, March 28, 2013 ª2013 Elsevier Inc. Open accesTherefore, MCC-L1-a, MCC-L1-b, and MCC-Alu were the
primary enactors of MCC transcriptional inhibition, potentially
assisted by other modifications to MCC or its upstream regula-
tory pathway.
Finally, we performed qRT-PCR to evaluate APC transcription
coincident with mutatedMCC. We found no significant differen-
tial transcription of APC in tumor or nontumor liver from the four
affected donors versus normal liver controls (Figure S2). In donor
95, APC was downregulated significantly in tumor versus non-
tumor (p < 0.003, t test, df = 4) but only by 30% versus normal
liver controls. By contrast,MCC-L1-a, the homozygous L1 inser-
tion in donor 95, severely reduced MCC transcription in both
tumor (83%) and nontumor (63%) samples compared with
normal liver controls (Figure 4B), demonstrating that the primary
effect ofMCC-L1-awas onMCC rather than APC. These data in
sum confirmed that (1) L1-mediated retrotransposition in MCC
specifically repressed MCC and not APC and (2) CTNNB1 was
strongly induced in all four affected individuals, indicating activa-
tion of a major HCC oncogenic pathway.
Somatic L1 Mobilization in HCC
Forty-five nonreference genome insertions were annotated as
tumor specific. These consisted of 17 L1, 27 Alu, and 1 SVA.
We first validated each L1 insertion with insertion site PCR, in-
cluding capillary sequencing of their 50 and 30 ends (Table S6).
All 17L1ssuccessfully amplified; 12confirmedas tumor-specific,
and5were found inboth tumor andnontumor liver. Further exam-
ination of the tumor-specific set revealed uniform usage of the
degenerate L1 endonuclease motif highlighted in Figure 2B. Ins under CC BY license.
Figure 3. Structure and Validation of Germ-
line L1 and Alu Insertions in MCC
(A) MCC mutant allele MCC-L1-a: a 5.3 kb L1-Ta
detected by RC-seq at its 50 and 30 ends in 70T,
70NT, 95T, and 95NT. The L1 was flanked by a 13
nt TSD. Primers used for PCR validation (1,2,3)
and RC-seq reads (red/white bars) are indicated
above the gene structure. Note: L1 not drawn to
scale.
(B) MCC mutant allele MCC-L1-b: a full-length
(6 kb) L1-Ta detected by RC-seq at its 50 and 30
ends in 116T and 116NT. The L1 was antisense to
MCC and was flanked by a 14 nt TSD. Primers are
indicated as for (A).
(C)MCCmutant alleleMCC-Alu: an AluY detected
by RC-seq at its 30 end in 33T and 33NT. The AluY
was antisense to MCC, had a 15 nt TSD, and
bisected an annotated enhancer (Thurman et al.,
2012). Primers (1,2) are indicated below the gene
structure.
(D) Insertion-site PCR validation confirmed that
MCC-L1-a, MCC-L1-b, and MCC-Alu were
present in the corresponding tumor and nontumor
samples (Table S5). The wild-type allele was
absent for donor 95, indicating a homozygous L1
insertion.two examples, PCR amplification of the 50 junction was repeat-
edly unsuccessful, preventing TSD characterization, an outcome
possibly due to gross genomic abnormality at the L1 insertion
site (Gilbert et al., 2002). Eight of the other integration sites incor-
porated TSDs, whereas the remaining two examples involved
small genomic deletions 30 of the insertion site and no TSD.
Somatic L1 mobilization occurred in donors 12, 15, 33, 47, and
89 (Table 1), with the latter individual presenting four insertions.
Two L1 copies (chr11:60136439 and chrX:99180431) were
greater than 5.3 kb in length, but no insertions were full-length.
All 12 somatic L1 insertions were from the L1-Ta subfamily.
We next evaluated 13 Alu insertions and the single SVA inser-
tion found only in tumor, using insertion site PCR. In all cases,
amplification occurred in both tumor and adjacent liver DNA,
indicating germline insertions. Our primary explanation for this
result is that there are several thousand potentially active AluY
copies in the genome, compared to fewer than 100 active L1s
(Bennett et al., 2008; Brouha et al., 2003). As seen previously,
the RC-seq read count per Alu is consequently 75% lower
than for L1 (Baillie et al., 2011), making false-negatives in the
nontumor control more likely for Alu than for L1. A secondary
explanation is that chromosomal gain is very common in HCC
(Guichard et al., 2012), increasing the probability that some
germline insertions are detected in tumor but not in adjacent
nontumor liver. A final possibility is that mutations in individual
precancerous cells are clonally amplified in tumors and are
called as tumor-specific by RC-seq and germline by insertionCell 153, 101–111, March 28, 2013 ª2013 Elsesite PCR. However, this was unlikely, as
we consistently observed strong PCR
amplification in both tumor and nontumor
liver in these cases. Consequently, RC-
seq reliably identifies new L1, Alu, andSVA mobilization events but requires insertion site PCR to
annotate tumor-specific insertions.
In recent work, we reported somatic L1 mobilization in the
normal brain but did not evaluate other organs (Baillie et al.,
2011). For the current study, somatic L1 insertions in nontumor
liver were considered difficult to evaluate because of the
frequent occurrence of chromosomal loss in tumors. In this
scenario, germline L1 insertions may be deleted in tumor but re-
tained in nontumor liver and called somatic events. Nonetheless,
we identified 21 L1 insertions restricted to nontumor liver in the
set putatively annotated as germline and as a proof-of-principle
experiment selected an example (chr13:27423763) for insertion
site PCR and capillary sequencing (Table S6). This 2.5 kb L1-
Ta insertion was detected only in liver and, interestingly, had
a long (127 nt) TSD (Figure S3). A germline L1 insertion deleted
in tumor cells would reasonably be expected to be detected in
the nontransformed cells (e.g., lymphocytes) infiltrating a tumor
(Unitt et al., 2005). Therefore, this very likely represented a
bona fide liver-specific somatic L1 insertion in the preneoplastic
liver of donor 47. Consequently, hepatocytes, or their progenitor
cells, may support limited somatic L1 mobilization, though the
contribution of this activity to malignancy remains unclear.
L1 Hypomethylation Enables Tumor-Specific
Mobilization
To assess whether L1 activity and L1 methylation state were
correlated in HCC samples, we performed bisulphite conversionvier Inc. 105Open access under CC BY license.
Figure 4. Downregulation of MCC
(A) Relative expression of MCC and CTNNB1 in control liver tissue compared
to tumor and nontumor liver tissue from donors 33, 70, 95, and 116. An
immunoblot performed against anti-MCC, anti-CTNNB1, and anti-GAPDH
(loading control) antibodies detected strong MCC expression only in controls
and strong CTNNB1 expression only in MCC mutant donors. MCC was also
detected weakly in donor 70NT, in line with qRT-PCR results shown in (B).
Expected protein molecular weights are marked on right. Note: anti-MCC and
anti-CTNNB1 antibodies produce double bands. See Figure S1 for donor 116
CTNNB1 immunohistochemistry.
(B) Downregulation of MCC transcription in MCC mutant donors: qRT-PCR
revealed thatMCCmRNA was significantly reduced compared to control liver
tissue in donors 33 (tumor only), 70 (tumor only), 95 (tumor and nontumor), and
116 (tumor and nontumor). **p < 0.002 and *p < 0.02, two-tailed t test, df = 19.
In all four donors, MCC was also strongly downregulated in tumor versus
nontumor samples (p < 0.0001, two-tailed t test, df = 10). Data are presented
as mean ± SD. See Figure S2 for APC qRT-PCR.
Figure 5. L1 Promoter Activation in HCC
(A) Bisulphite analyses in HCC patients versus controls revealed a significant
decrease in L1 promoter methylation in tumor samples. Each column repre-
sents the methylation of 20 CpG residues found within the internal L1-Ta
promoter. Values are presented as the mean percent of CpG methylation ±
SEM (***p < 0.0005, ****p < 2.53 1018, chi-square test). Please see Figure S4
for detailed analysis.
(B) TaqMan qRT-PCR measurement of L1 ORF2 indicated significantly in-
creased L1 transcription in tumor and adjacent matched liver tissue versus
controls. Data for each group (tumor, nontumor, and control) were pooled and
presented as mean ± SEM (**p < 0.003, two-tailed t test, df = 22, Bonferroni
correction).
(C) As for (B), except observed at the L1 50 UTR (*p < 0.006). Please see Fig-
ure S3 for an example of a somatic L1 insertion in nontumor liver.of gDNA and capillary sequenced the CpG island present in the
canonical L1 promoter. Eight tumors (15T, 47T, 48T, 62T, 89T,
95T, 106T, and 116T) matched adjacent liver samples, and
control liver samples were analyzed. In the tumor group,
54.8% of L1-promoter CpG dinucleotides were methylated,
compared with 69.2% in nontumor liver, a strongly significant
difference (p < 2.5 3 1018, chi-square test, n = 8) (Figure 5A).
On average, all but one CpG was hypomethylated in tumor,
with the remaining CpG being equally methylated in tumor and
nontumor liver (Figure S4A). Hypomethylation was not observed
in grouped adjacent nontumor liver tissue versus controls.
As shown in Figure S4B, a subset of four individuals (donors
47, 89, 106, and 116) presented much stronger L1-promoter
hypomethylation in their tumor (40.5%) versus nontumor liver
(72.3%) samples compared with the remaining individuals
(69.2% versus 66.1%). The three individuals with tumor-specific
L1 insertions and L1 methylation data (donors 15, 47, and 89)
yielded a strong correlation between L1 hypomethylation per-
centage and tumor-specific L1 insertion count (r = 0.97; n = 3).
Donor 89 exhibited the strongest tumor-specific L1 hypomethy-106 Cell 153, 101–111, March 28, 2013 ª2013 Elsevier Inc. Open acceslation and also had the most tumor-specific L1 insertions (Fig-
ure S4C). Donor 15 showed only tumor-specific hypomethylation
distal to the L1 50 end, whereas donors 47 and 89 were hypome-
thylated across the L1 promoter (Figure S4C).
Hypomethylation of the L1 promoter enables transcription
of full-length L1 mRNAs that are translated to form the L1 mobi-
lization machinery (Ostertag and Kazazian, 2001a). We therefore
used cDNA synthesized with L1-specific primers (Wissing et al.,
2012) to quantify L1 expression levels by TaqMan qRT-PCR. In
this analysis, wemeasured L1mRNA levels using primers target-
ing L1 ORF2 (Figure 5B) and the L1 50 UTR (Figure 5C). In boths under CC BY license.
Figure 6. A Tumor-Specific L1 Insertion
Causes Induction of ST18
(A) ST18 mutant allele: a 0.4 kb L1-Ta insertion
antisense to ST18. Primers used for PCR valida-
tion (1,2) are indicated above the gene.
(B) L1 insertion, magnified view: RC-seq detected
the L1 50 and 30 termini, indicating a 17 nt TSD and
a 50 inversion.
(C) Insertion-site PCR validation: the L1 was
detected only in 47T, whereas the empty site was
found in both 47T and 47NT.
(D) qRT-PCR: ST18 was upregulated 4-fold in 47T
versus 47NT (*p < 0.005, two-tailed t test, df = 4).
Data are presented as mean ± SD.
(E) ST18 immunoblot: ST18 (115 kDa) was en-
riched in 47T versus 47NT and normal liver
controls.
(F) ST18 immunohistochemistry: accumulation of
ST18 (brown) was observed in tumor nodules
compared to surrounding nontumor regions.
Nuclei were stained with hematoxylin (blue).
(G) A palindromic sequence motif was bisected by
the L1. Each 8 nt unit (a and b, light green) con-
tained a subsequence 1 nt different to a PIT1-
enhancer motif known to bind MYT1 (Rhodes
et al., 1993). A second motif 58 bp from the L1
integration site matched the consensus CEBPA
binding motif (orange).
(H) ChIP followed by quantitative real-time PCR in
Huh7 cells confirmed enrichment for ST18 bound
to the putative ST18-enhancer element illustrated
in (G), compared to GAPDH. Data from antibodies
targeting both the N termini and C termini of ST18
are shown. Significance values were calculated
using two-tailed t tests (df = 4). Data are presented
as mean ± SD.
Please see Tables S6 and S7 and Figures S5
and S6 for further information regarding tumor-
specific L1 insertions and additional ST18 char-
acterization.cases, significant enrichment was observed in tumor and non-
tumor versus normal controls (p < 0.003 for ORF2, p < 0.006
for 50 UTR, t tests, df = 22). Together, these data showed that
L1 was activated and transcribed in HCC, coincident with hypo-
methylation of the L1 promoter.
ST18 Activated by a Tumor-Specific L1 Insertion
Tumor-specific L1 insertionswere observed in six protein-coding
genes (Table S6). Quantitative RT-PCR indicated that two of
these genes (STXBP5L and SLC5A8) were not expressed in liver.
The expression of three other genes was reduced 2-fold to 6-fold
in tumor versus adjacent liver (p < 0.05, t test, df = 4), including
a 30 UTR insertion in SLC2A1 and intronic insertions in PHGDH
and EFHD1 (Figure S5). These examples resemble those seen
in other cancers in which intragenic L1 insertions in tumors coin-
cided with reduced host gene expression (Lee et al., 2012). To
our knowledge, downregulation of SLC2A1, PHGDH, or EFHD1
has not previously been associated with cancer.
The remaining tumor-specific L1 insertion occurred in donor
47 and was associated with activation of the transcriptionalCell 153, 101–111, Marepressor suppression of tumorigenicity 18 (ST18), a member
of the MYT1 zinc-finger transcription factor family (Yee and Yu,
1998). Contrasting reports depict ST18 as a tumor suppressor
and as an oncogene in different cancers (Jandrig et al., 2004;
Steinbach et al., 2006). ST18 is, however, very poorly expressed
in liver (Jandrig et al., 2004), making it unlikely to act as a tumor
suppressor in this context. Ectopic host gene expression was an
unusual consequence of an L1 insertion given that these events
are usually repressive (Han et al., 2004). As such, we hypothe-
sized that ST18 was a candidate liver oncogene activated via
an unknown mechanism triggered by an intronic L1 insertion.
Initial data from RC-seq indicated a heavily 50 truncated,
410 bp L1-Ta arranged antisense to ST18 (Figure 6A). The
integration site incorporated a 17 nt TSD, a degenerate L1 endo-
nuclease motif (GC/AAAA), and a 112 bp 50 inversion of the L1
(Figure 6B), consistent with twin priming (Ostertag and Kazazian,
2001b). We then confirmed these features by PCR amplification
and capillary sequencing of the L1 50 and 30 junctions, indicating
a tumor-specific L1 insertion (Figure 6C). PCR on DNA extracted
from three distinct biopsies taken from the same tumor detectedrch 28, 2013 ª2013 Elsevier Inc. 107Open access under CC BY license.
the L1 in all three regions, suggesting clonal amplification of
tumor cells with the L1 mutant ST18.
As noted above, qRT-PCR indicated that ST18 expression
was significantly increased in tumor versus adjacent nontumor
liver (p < 0.005, t test, df = 4) (Figure 6D). To corroborate this
result, we performed an immunoblot and immunohistochemistry
with an anti-ST18 antibody and found ST18 was indeed ectopi-
cally expressed in donor 47 tumor (Figures 6E and 6F). Chromo-
somal gain and regional copy number variation (CNV) have
previously been reported for chromosome 8q, the genomic
region containing ST18 (Guichard et al., 2012). However, quanti-
tative real-time PCR on gDNA indicated no ST18 CNV in donor
47 tumor. Thus, tumor cells containing the ST18 L1 mutation
were clonally amplified without CNV of the ST18 locus, followed
by ST18 transcriptional activation.
In response, we predicted that ST18 was activated by inser-
tional mutagenesis of a cis-regulatory element proximal to the
L1. In silico analysis of the L1 integration site indicated that it
bisected a palindromic motif containing two 8 bp units differing
by one nucleotide and separated by 3 bp (Figure 6G). The prob-
ability of a random insertion in this motif, even allowing for
a mismatch in the palindrome and a generous gap of %11bp,
was less than 1/1,000 (permutation test). Intriguingly, each unit
was only one nucleotide different to a strong MYT1 binding motif
found in the enhancer of PIT1 (Rhodes et al., 1993). Previous
experiments predicted that these units would bind MYT1 with
reduced efficiency (Jiang et al., 1996), though transcription
factors incorporating two zinc-finger domains, as for MYT1,
are known to greatly gain efficiency through binding tandem
DNA motifs (Yee and Yu, 1998). The putative MYT1 binding
site was proximal to a strong binding site for CEBPA, a transcrip-
tion factor enriched in liver and known to bind active enhancers
(Johnson et al., 1987).
Based on this computational analysis, we predicted that the
L1 bisected an enhancer normally bound to the zinc fingers of
the ST18 MYT1 domain. To test this experimentally, we per-
formed chromatin immunoprecipitation (ChIP) of DNA bound to
the ST18 protein in Huh7 cells, followed by PCR amplification
of the putativeST18 enhancer. This assay confirmed that, absent
an L1 insertion, ST18 was preferentially bound to its own
enhancer (p < 0.0004, t test, df = 4) (Figure 6H). An L1 insertion
in the ST18 binding site would reasonably be expected to
displace this repressive mark from the enhancer. Thus, we
experimentally validated a model of ST18 activation in which
a negative feedback loop was interrupted by a tumor-specific
L1 insertion.
Finally, in view of the clonal amplification of tumor cells con-
taining ectopically expressed ST18, we engaged complemen-
tary in vitro and in vivo experimental models to assess ST18
oncogenic function in HCC. Although ST18 is poorly expressed
in liver, we found it to be abundant in several liver cancer cell
lines (Figure S6A). We then determined the frequency of ST18
CNV in an Mdr2/ mouse model of inflammation-driven HCC.
TaqMan quantitative real-time PCR detected ST18 amplification
in 4/23 Mdr2/ HCC nodules and no deletions (Table S7). A
disproportionately high percentage of advanced tumors (75%)
presented ST18 amplification. ST18 expression was also signif-
icantly higher in nodules with amplified ST18 compared with108 Cell 153, 101–111, March 28, 2013 ª2013 Elsevier Inc. Open acceswild-type mouse liver (p < 0.0001, t test, df = 19) (Figure S6B).
These experiments demonstrate concordance of frequent
ST18 amplification and upregulation in human and mouse
models of HCC, results consistent with ST18 functioning as
a candidate liver oncogene.
DISCUSSION
The present study highlights endogenous L1-mediated retro-
transposition in the germline and somatic cells of HCC patients.
We report two archetypal mechanisms revealingMCC and ST18
as HCC candidate genes. MCC is, for the many reasons high-
lighted above, a highly plausible liver tumor suppressor. Four
out of 19 individuals studied here, including two cases each of
HBV and HCV infection, presented distinct germline L1 or Alu
insertions contributing to MCC suppression in tumor and non-
tumor liver tissue. Strong upregulation of CTNNB1 in all four
donors was consistent with prior observations that CTNNB1 is
inhibited by MCC (Fukuyama et al., 2008). It is also interesting
that MCC-L1-a was homozygous in donor 95, and therefore,
MCC was almost certainly downregulated in the liver of this
patient prior to HBV infection, i.e., preceding viral challenge,
cirrhosis, and tumorigenesis.
We also demonstrate that MCC transcriptional repression in
all four affected donors was exclusive of APC. Mutated APC
is common in colorectal cancer but rare in HCC (Guichard
et al., 2012; Powell et al., 1992). Even in colon, MCC presents
numerous properties of a tumor suppressor (Bouwmeester
et al., 2004; Fukuyama et al., 2008; Kohonen-Corish et al.,
2007; Matsumine et al., 1996). Indeed, a Sleeping Beauty trans-
poson mutagenesis screen using a mouse model of colorectal
cancer found specific mutations in MCC and APC at a 1:9 ratio
(Starr et al., 2009). Very recently, exome resequencing identified
sporadic MCC point mutations in HCC (Guichard et al., 2012).
Thus,MCC has potential to act as a liver tumor suppressor inde-
pendent of APC, and our results support this potentially pivotal
line of enquiry.
Tumorigenic retrotransposition in somatic cells was first ob-
served 20 years ago, coincidentally in the APC gene of an indi-
vidual with colorectal cancer (Miki et al., 1992). High-throughput
sequencing has since provided the means to test whether
tumor-specific retrotransposition is a common feature of cancer.
Our results indicate that L1 mobilization occurs in a minority of
HCC tumors, adding to the list of epithelial cancers (lung, colon,
ovarian, and prostate) known to support the phenomenon (Iskow
et al., 2010; Lee et al., 2012; Miki et al., 1992; Solyom et al.,
2012). Although transformed tumor cells, including liver cancer
cell lines, support frequent transgenic L1 mobilization (Moran
et al., 1996), it is unknown whether endogenous L1 activation
precedes neoplastic transformation in vivo. For this reason, it
was interesting that L1 transcription was found in liver tissue
adjacent to tumors, in addition to an example of somatic L1
mobilization. Finally, in a small cohort of tumor-specific L1 inser-
tions, we identified mobilization via TPRT, twin priming, and
a third mechanism resulting in a small deletion and no TSD, as
reported elsewhere (Gilbert et al., 2002). These observations
highlight the multiple routes by which L1 mobilization alters the
tumor cell genome.s under CC BY license.
The results presented here corroborate recent data generated
via whole-genome sequencing of other cancers. As in our study,
Lee et al. (2012) described tumor-specific L1 insertions bearing
the hallmark features of TPRT and also found intragenic L1 inser-
tions in differentially expressed genes (Lee et al., 2012). One
distinct feature of the current study is our discovery that germline
L1 and Alu insertions significantly perturb expression of genes
relevant to HCC. Another advance is our explanation for the
occasional activation of host genes by tumor-specific L1 inser-
tions, based on an example of an interrupted negative feedback
loop. The method presented by Lee et al. (2012) is convenient
inasmuch as existing whole-genome sequencing data can be re-
analyzed to identify novel retrotransposon insertions. However,
we generated similar results with per sample sequencing depth
1/12 that of Lee et al. (2012), suggesting RC-seq is more efficient
for new studies specifically focused on retrotransposons.
L1-mediated insertional mutagenesis revealed ST18 as a
candidate oncogene in HCC. Numerous corroborating observa-
tions support this possibility, including (1) clonal amplification of
tumor cells containing the L1mutantST18, (2) ectopic ST18 tran-
scription and translation in tumor not seen in adjacent nontumor
liver or control liver, (3) consistent ST18 expression in trans-
formed liver cancer cell lines, (4) frequent amplification of ST18
in HCC nodules taken from Mdr2/ mice, and (5) induction of
ST18 transcription in those animals. However, we do not make
any conclusion regarding the function of ST18 as a tumor
suppressor or oncogene outside of the liver and draw attention
in this matter to KLF4, a transcriptional repressor known to func-
tion as a tumor suppressor and as an oncogene, depending on
context (Rowland et al., 2005).
Overall, our results illustrate the confluence of multiple genetic
aberrations in HCC, where inherited and de novo retrotransposi-
tion events form part of a wider mutational landscape. The
experiments presented here and elsewhere suggest L1 activity
varies substantially between individuals and cancer types (Iskow
et al., 2010; Lee et al., 2012; Solyom et al., 2012). It remains to be
proven whether this phenomenon correlates with prognosis, is
useful in a diagnostic capacity, or can be subjected to exoge-
nous interference in vivo. Nonetheless, we can conclude that
L1-mediated retrotransposition is a potentially crucial source of
mutations that can reduce the tumor suppressive capacity of
somatic cells in HCC.
EXPERIMENTAL PROCEDURES
Full protocols can be found in the Extended Experimental Procedures.
Samples
Tumor and nontumor liver tissues from 19 HCC patients with a confirmed HBV
or HCV infection were provided by the Centre He´patobiliaire, Paul-Brousse
Hospital. DNA and RNA were extracted with a DNeasy Blood and Tissue Kit
(QIAGEN, Hilden, Germany) and a mirVana miRNA Isolation Kit (Life Technol-
ogies, Carlsbad, CA, USA), respectively. Control liver samples from five donors
were provided by the Edinburgh Sudden Death Brain and Tissue Bank. DNA
and RNA were isolated through standard phenol-chloroform extraction and
RNA-Bee RNA isolation reagent (Tel-Test), respectively. Samples were
analyzed with approval from the French Institute of Medical Research and
Health (Ref: 11-047), the East of Scotland Research Ethics Service (Ref:
LR/11/ES/0022), and the Mater Health Services Human Research Ethics
Committee (Ref: 1915A).Cell 153, 101–111, MarchRC-Seq Library Preparation, Sequencing, and Analysis
Multiplexed DNA sequencing libraries were constructed for HCC tumor and
nontumor samples using a paired-end Illumina TruSeq Kit with substantial
modifications. Briefly, 1 mg of sonicated DNA size selected for an insert size
of 200–250 bp was used for each library and amplified by six cycles of liga-
tion-mediated PCR (LM-PCR). Libraries were then pooled in groups of 4 to 6
and hybridized to an updated custom Roche NimbleGen sequence capture
array comprising oligos tiling the 50 and 30 termini of active human retrotrans-
poson consensus sequences (Figure 1; Table S1). Libraries were again ampli-
fied by six cycles of LM-PCR and sequenced on an Illumina HiSeq2000. After
quality filtering, each read pair was assembled into a contig, aided by 23 150-
mer sequencing and a 220 nt insert size. Read contigs were then aligned to
retrotransposon consensus sequences to determine their retrotransposon
donor family, aligned to the human reference genome (hg19) to determine their
genomic position, and finally formed into clusters.
PCR Validation
Germline retrotransposon insertions detected by RC-seq were first validated
by a standard empty site/filled site PCR assay and then, if unsuccessful,
with PCR targeting an insertion site 50 or 30 end. Tumor-specific insertions
were characterized with a similar strategy but also incorporated 50 and 30
end capillary sequencing. All validation was performed on nonamplified DNA
stored and handled separately from postamplification RC-seq products.
Primers were designed using custom Python scripts and Primer3.
qRT-PCR
Complementary DNA was synthesized from total RNA using random hexam-
ers, except for L1 analyses, where a specific sense L1 primer was used.
qRT-PCR was performed using a LightCycler 480 (Roche, Indianapolis, IN,
USA), and values were normalized to TATA-binding protein (TBP). For primer
sequences, see Table S8.
ACCESSION NUMBERS
RC-seq FASTQ files were deposited in the European Nucleotide Archive
(ERP001476).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and eight tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2013.02.032.
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